Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • University of Michigan • EGFR+ • ALK+

Answer from: Medical Oncologist at Community Practice

The PACIFIC study represents an important advancement for patients with unresectable, stage III NSCLC. The initial OS results were presented recently and demonstrated a significant improvement in survival for patients receiving durvalumab following chemoradiation. The median time has not been reach...

Comments

Medical Oncologist at Virginia Cancer Specialists
With even lower numbers of patients with ALK gene ...

Medical Oncologist at The Oncology Institute of Hope and Innovation
I am curious about this too. Any opinions or comme...

Answer from: Medical Oncologist at Academic Institution

This is a highly controversial topic that frequently arises and I think there are multiple plausible interpretations of the PACIFIC data. I previously posted on this topic [see https://www.themednet.org/question/18570], but I generally do not offer durvalumab for these patients. I anticipate the LAU...

Related Questions